In 2015, the Diabetic Retinopathy Clinical Research Network reported a randomized clinical trial to compare the effectiveness between different intravitreal VEGF inhibitor therapies, which found that 11–12% of participants in each treatment group developed self-reported adverse renal effects during the 1-year follow-up [34]. The gene discussed is VEGFA; the disease is diabetic retinopathy.